MSD has announced that they will discontinue the production of immunotherapy in Oss and consolidate it at a few locations outside the Netherlands. These locations will produce immunotherapy in a modified manner to meet the global demand of MSD. In addition to discontinuing the production of immunotherapy, they also intend to cease certain laboratory activities at the Moleneind location in Oss and transfer them to other sites. Currently, discussions are underway with various parties to discuss the future of the Oss site, with the goal of preserving maximum employment, production, and innovation capacity for the Netherlands. MSD will continue to have an active presence in Oss with international (office) functions.